top of page

Checking in with Alector CEO Arnon Rosenthal ahead of a pivotal trial readout for latozinemab in frontotemporal dementia in the fourth quarter

Aug 12, 2025

1 min read

Dr. Rosenthal describes the unmet need in frontotemporal dementia and mechanism of action of latozinemab. He covers the trial design and explains why a new co-primary endpoint was recently added to the statistical plan. Plus, developing a similar medicine for early stage Alzheimer's, and how Alector is trying to get therapies across the blood-brain barrier more efficiently.

https://vimeo.com/1109525866?share=copy

Recent Posts

At its R&D Day in London today, Gubra provided updates on obesity assets licensed to AbbVie and Boehringer Ingelheim, as well as highlighted its lead internal program UCN2

At its R&D Day in London today, Gubra provided updates on obesity assets licensed to AbbVie and Boehringer Ingelheim, as well as highlighted its lead internal program UCN2

Earlier this month, Agilent agreed to acquire Philadelphia based Proscia, a provider of digital pathology software for clinical and life-sciences customers, for $240M up front and up to $30M more

Earlier this month, Agilent agreed to acquire Philadelphia based Proscia, a provider of digital pathology software for clinical and life-sciences customers, for $240M up front and up to $30M more

Immuneering Co-Founder & CEO Ben Zeskind discusses the future of the third generation MEK inhibitor atebimetinib, which has shown promising data in first line pancreatic cancer

Immuneering Co-Founder & CEO Ben Zeskind discusses the future of the third generation MEK inhibitor atebimetinib, which has shown promising data in first line pancreatic cancer

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

10x_Genomics_logo.svg.png

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

Mispro is an AAALAC-accredited contract vivarium organization (CVO) offering a network of full-service vivarium rental lab facilities for preclinical in vivo rodent studies. Along with access to state-of-the-art lab spaces, Mispro supports its clients with comprehensive laboratory animal research services, including husbandry, veterinary, technical, and regulatory compliance oversight. With locations in all major U.S. biotech hubs, Mispro is committed to helping biosciences companies of all sizes and therapeutic indications achieve their research goals.

bottom of page